This educational program is intended for dermatologists, oncologists, and other healthcare professionals who treat patients with nonmelanoma skin cancers.
The goal of this program is to improve the knowledge and competence of dermatologists, oncologists, and other healthcare professionals treating patients with nonmelanoma skin cancer to incorporate newer patient-centered therapies into therapeutic regimens to improve clinical outcomes.
Upon completion of this activity, participants should be able to:
Identify patients with BCC who could benefit from immunotherapy
Plan therapeutic strategies using immune checkpoint inhibitor–based treatments for patients with advanced BCC, considering current safety and efficacy data and expert recommendations
Determine optimal treatment for patients with locoregionally advanced or metastatic cutaneous squamous cell carcinoma who are not eligible for curative treatment with surgery or radiation therapy
Apply available clinical data to guide decisions on the use of immunotherapy in the management of metastatic MCC
Manage immune-related adverse events promptly in patients with nonmelanoma skin cancer who are receiving immune checkpoint inhibitor therapy to afford patients optimal benefit from treatment
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Zeynep Eroglu, MD
Assistant Professor of Oncologic Sciences
Department of Oncologic Sciences
University of South Florida
Department of Cutaneous Oncology
H. Lee Moffit Cancer Center & Research Institute
Zeynep Eroglu, MD: consultant/advisor/speaker: Boehringer-Ingelheim, Eisai, Genentech, Pfizer, Regeneron
Bethany Withycombe, PharmD, BCOP
Clinical Pharmacy Specialist, Cutaneous Clinic
Moffit Cancer Center
Bethany Withycombe, PharmD, BCOP, has no relevant financial relationships to disclose.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 09, 2023, through May 08, 2024:
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.00 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-130-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.